Announced
Synopsis
PacBio, a developer of high-quality, highly accurate sequencing solutions, agreed to acquire Apton Biosystems, a company developing a high throughput short-read sequencer using state-of-the-art optics and image processing, for $110m. "I am impressed with Apton's progress in developing a novel, high throughput sequencing platform that has the potential to deliver very low-cost sequencing at tremendous scale. By integrating our highly accurate SBB technology with Apton's advanced optics and image processing capabilities, PacBio expects to commercialize a high throughput short-read platform faster than we had planned. This acquisition is consistent with our strategy to develop a multiproduct short-read sequencing portfolio alongside our long-read sequencing platforms, giving us an opportunity to reach an even greater portion of the multi-billion-dollar sequencing market," Christian Henry, PacBio President and CEO.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.